The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy ...

在国家自然科学基金项目（批准号：82020108013）等资助下，首都医科大学宣武医院韩璎教授团队联合德国科隆大学Frank Jessen教授团队在阿尔茨海默病（Alzheimer's disease, AD）疾病早期预测研究方面取得进展。研究成果以 ...

Alzheimer's disease is likely caused by stalled protein processing in the brain, according to a new study. The research, ...

Researchers have uncovered a link between COVID-19 and blood markers linked to faulty proteins in the brain. The analysis, ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

Scientists believe the disease is caused when a protein called amyloid beta accumulates in the brain. Conventional dementia medications are designed to relieve symptoms by activating certain ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

Exercise may positively influence the interactions between brain cells in the hippocampus, a brain region involved in ...